ARWR Jun 2024 22.500 call
| Previous close | 1.8500 |
| Open | 3.1000 |
| Bid | 2.9000 |
| Ask | 4.1000 |
| Strike | 22.50 |
| Expiry date | 2024-06-21 |
| Day's range | 3.1000 - 3.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 186 |
Business WireArrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
PASADENA, Calif., June 03, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducing t
Business WireArrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
PASADENA, Calif., May 31, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
Business WireArrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
PASADENA, Calif., May 29, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with robust and durable reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation today at the Euro
